Lundbeck launches a phase II study for potential new treatment of multiple system atrophy
Lu AF82422 represents a novel approach for potential treatment of multiple system atrophy (MSA), which currently represents a high and urgent unmet medical need.H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is ready to initiate the AMULET study, which is designed to confirm the potential of Lu AF82422 as a treatment to slow the rate of disease progression of multiple system atrophy (MSA). MSA is a serious, rare, sporadic, and rapidly deteriorating neurodegenerative disease that gradually damages brain cells. Current therapeutic intervention is